CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.
Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
继发于CAR-T 细胞治疗的免疫效应细胞相关神经毒性综合征(ICANS)在复发/难治性(R/R)B细胞急性淋巴细胞白血病(ALL)成人患者中常见,但该患者人群中神经毒性期间的影像学表现及其意义尚未被系统描述。Brexucabtagene autoleucel(brexu-cel)是一种靶向CD19的自体T细胞免疫疗法,用于治疗R/R B细胞ALL成人患者,可进入中枢神经系统。我们报告一例R/R B细胞ALL且既往有软脑膜病变的成人患者,在接受brexu-cel治疗期间出现神经毒性及脑磁共振成像新发现。我们在临床背景下解读该患者的神经影像学检查,以区分ICANS与残留白血病的活动性治疗。
Immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to chimeric antigen receptor T-cell therapy is common in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), but imaging findings during neurologic toxicity and their meaning have yet to be systematically described in this patient population. Brexucabtagene autoleucel (brexu-cel) is a CD19-directed autologous T-cell immunotherapy for the treatment of adult patients with R/R B-cell ALL that can enter the central nervous system.
We present a case of an adult patient with R/R B-cell ALL and prior leptomeningeal disease who developed neurologic toxicity and new findings on magnetic resonance imaging of the brain while receiving brexu-cel.
We interpret the patient's neuroimaging studies within clinical context to differentiate ICANS from active treatment of residual leukemia.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。